Lcr Ventures Limited

This project will sit alongside a Future Medicines Accelerator(FMA) already approved for funding by IUK, launching September 2025. Recruitment to a Pre-Accelerator within the FMA will be expanded, to include a cohort of SMEs developing radiopharmaceuticals and/or advanced therapies for cancer, eight of which will then be selected for this Radiopharmaceuti...

This Future Medicines Accelerator project brings together an internationally recognised consortium of scientific and technical leaders in the field of future medicines, with world-leading expertise alongside commercialisation and investment experts. The project is led by LYVA Labs partnering with: * Bionow * Medicines Discovery Catapult (MDC) * Cell & Gen...

**Cardiomyopathy** is a disease that affects the heart muscle and can cause heart failure and sudden death. The most common genetic type of this disease is called hypertrophic cardiomyopathy, which thickens the heart. In the last few years, the first of new drugs and gene therapies have been developed to treat this disease more precisely. These are real b...

no public description

Liverpool City Region Combined Authority (LCR CA) has developed an Innovation Prospectus for the region and set itself two ambitious targets: 1. increase current 2% GVA spend on R&D to 5% by 2030 2. achieve net zero by 2040 (10 years ahead of the national target) LYVA Labs was established in 2021, with funding from LCR CA, with the aim of becoming a susta...

This industrial research project aims to validate our existing Artificial Intelligence guiding system prototype aimed at guiding surgeons during Intramedullary Nailing (IM) surgeries in less time, with less radiation, generating fewer risks to both patients and medical personnel. Surgical techniques for IM have remained largely unchanged for decades. IM s...